New endometriosis diagnostic tests emerge
Analysis based on 17 articles · First reported Sep 05, 2026 · Last updated Sep 05, 2026
The emergence of new endometriosis diagnostic tests could expand the market for non-invasive diagnostics, benefiting developers like EndoSure and Ziwig. Regulatory approvals and adoption by health systems like the NHS may drive revenue growth, though U.S. market entry faces regulatory hurdles.
Endometriosis UK, a chronic inflammatory disease affecting 1 in 10 women worldwide, often goes undiagnosed for a decade or more due to symptom normalization and lack of provider expertise. New diagnostic tests, EndoSure and Endotest, are now available in some countries outside the U.S. EndoSure, developed by Maryland-based EndoSure, measures electrical signals in the gut via abdominal sensor pads. Endotest, developed by French company Ziwig, analyzes saliva for microRNAs. The United Kingdom's United Kingdom — National Health Service has published draft guidance recommending both tests for three years to speed diagnosis in primary care. EndoSure is submitting an FDA application in the U.S., while Ziwig is pursuing availability through certified laboratories without FDA approval. U.S. doctors view these tests as helpful adjuncts, not replacements, for existing diagnostic methods. Patient Zoë Armstrong, diagnosed after years of symptoms, underwent excision surgery and advocates with the Endometriosis Foundation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard